ArticleBMC infectious diseases2024
Analysis of the epidemiological trends of Tuberculosis in China from 2000 to 2021 based on the joinpoint regression model.
Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Trends and spatial distribution of pulmonary tuberculosis in China: a surveillance study.Frontiers in public health · 2026Article
- Machine learning identifies environmental drivers of pulmonary tuberculosis in Xinjiang a typical arid region of China.Scientific reports · 2025Article
- Trends in epidemiological characteristics of pulmonary tuberculosis among children and youth in Chinese mainland from 2019 to 2024: analysis of national surveillance data.BMC public health · 2025Article
- Analyzing factors affecting tuberculosis incidence in various mainland Chinese economic regions and predicting trends: a comprehensive regression study.BMC public health · 2025Article
- Analysis of regional characteristics in mortality trends of three chronic infectious diseases among the elderly in China, 2004-2021.Infectious diseases of poverty · 2025Article
- Global trajectory and spatiotemporal epidemiological landscape of multidrug-resistant tuberculosis of spanning 46 years (1990-2035): implications for achieving global end TB goals.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChina is ranked third globally in terms of burden and has a moderately high to high prevalence of tuberculosis (TB). This study meticulously investigated the notification rates of TB and assessed the epidemic in China from 2000 to 2021. The aim of the study was to provide robust supporting data that is crucial for enhancing TB prevention and control strategies.
methodsExtensive data regarding TB notification rates in China between 2000 and 2021 was collected. The joinpoint regression model was subsequently utilized to assess the temporal trends in the notification rates of TB, which were analyzed through the annual percentage change (APC) and the average annual percentage change (AAPC).
resultsDuring the study period (2000-2021), the standardized notification rates of TB in China ranged from 38.89/100,000 to 101.15/100,000, with a significant annual average decrease of 4.43% (P < 0.05). Before the COVID-19 pandemic, a marked acceleration in this decline was observed from 2006 to 2015, with an APC of 4.62% (P < 0.05). Stratified by age and sex, the age group with the most significant annual decline in overall standardized notification rates of TB among males in China was < 15 years old, followed by 55-64 years old, and the group with the least decrease was 25-44 years old. Similarly, the age group with the most significant annual decline in standardized notification rates of TB among females was < 15 years old.
conclusionsThe epidemic of TB in China exhibited a downward trajectory between 2000 and 2021. However, it is imperative to prioritize the attention given to males and older adults, and to promote specific and effective prevention and control strategies for these populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.